Eisai Innovation

Eisai Innovation

Eisai Innovation was founded in 2019 as the corporate venture investment arm of Eisai Co., Ltd., a publicly traded Japanese pharmaceutical company with roughly 10,000 employees. President Yoshiharu Mizui, a discovery research biologist with more than two decades at Eisai, built the unit after leading the oncology business group's BD and strategy function and helping found the Cambridge-based subsidiary H3 Biomedicine. The vehicle deploys the parent company's balance sheet to acquire innovation that Eisai's internal R&D does not generate. The firm makes equity investments of approximately $5 million per transaction across biotechnology, drug modalities, digital healthcare, and diagnostics. It concentrates on neurology and oncology — the two therapeutic areas where Eisai's commercial organization is deepest — while also scanning emerging markets in Africa alongside established hubs in the United States, Europe, Japan, and China. The mandate spans early-stage startups through pre-exit assets on a roughly ten-year hold period, and the team actively pursues M&A when a target fits Eisai's long-term strategy. The firm's posted goal is to help push the parent into the top ten global healthcare companies by revenue. Managing Director Kou Qin, a Harvard-trained neuroscientist, runs the Cambridge investment operation and joined in 2021 from MSA Capital, where he led global healthcare strategy. Investment Principal Paul Wu covers the West Coast from San Francisco, having previously made early-stage biotech and digital-health bets at Grey Sky Venture Partners. The parent, Eisai Co., fields a global workforce of approximately 10,000 and operates regional subsidiaries in the United States and Europe; the innovation unit funnels portfolio companies into that commercial infrastructure when technologies mature. Eisai Innovation operates with full balance-sheet backing rather than a blind-pool fund structure, which removes the pressure of a fixed fundraising cycle and lets the team hold positions for the ten-year window its website describes. This corporate venture model ties returns not to management fees or carry but to the strategic value a portfolio company delivers to Eisai's pipeline — a governance structure that aligns investment decisions with the parent's neurology and oncology franchises. The firm explicitly invites academic-founded startups and cold inbound pitches through its website, signaling a sourcing posture wider than what a typical in-house corporate-development group would pursue.